We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Nazli Dizman

Nazli Dizman MD

Postdoctoral Research Fellow, City of Hope Comprehensive Cancer Center, Duarte, California

Dr. Nazli Dizman is a postdoctoral fellow in the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center in Duarte, California. She graduated from Ege University School of Medicine in Izmir, Turkey, and completed her internal medicine residency training at Istanbul Medeniyet University School of Medicine in Istanbul, Turkey.

Dr. Dizman is involved in clinical and translational research projects in the area of genitourinary cancers since 2016. She has played crucial roles in the planning, initiation and management of several clinical studies examining the role of clinical factors, genomics, and the microbiome in genitourinary cancer outcomes. Dr. Dizman has published over 25 peer-reviewed articles in scientific journals and presented several abstracts at national and international meetings.

Disclosures

No disclosures reported.

Recent Contributions to PracticeUpdate:

  1. Metastatic Renal Cell Carcinoma Patient With Indolent Disease
  2. Management of Rare RCC Subtypes—Chromophobe Renal Cell Carcinoma
  3. Management of Rare RCC Subtypes - Translocation RCC
  4. Management of Rare RCC Subtypes - Renal Medullary Carcinoma
  5. Systemic Therapy for mRCC Patient on Hemodialysis
  6. Genetics Consultation in RCC Patient
  7. ASCO: Cabozantinib and Atezolizumab in Urothelial Cancer
  8. ASCO: Early Data on the Gut Microbiome and Outcomes in RCC
  9. Progression After Immunotherapy in Patient With Recurrent RCC
  10. The Society for Immunotherapy of Cancer Consensus Statement on Immunotherapy for Advanced RCC

Most Read This Week

Recently Updated